

## Company Overview

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system conditions. The company has five novel and differentiated drug development programs. OLINVYK™ is approved by the FDA. Please see **Important Safety Information** including **Boxed Warning** in the full prescribing information available at [OLINVYK.com](http://OLINVYK.com). The company has four investigational drug candidates including TRV 027 for acute respiratory distress syndrome and abnormal clotting, TRV 250 for the acute treatment of migraine and TRV 734 for maintenance treatment of opioid use disorder. The company has also identified TRV 045, a novel S1P receptor modulator that may offer a new, non-opioid approach to managing chronic pain and CNS disorders.

## Trevena Announces Presentation of OLINVYK® Respiratory Safety Data in High-Risk Patients at the 46th Annual ASRA Meeting

May 12 2021, 7:00 AM EDT

## Trevena Announces TRV027 Selected by NIH-Funded ACTIV Initiative For COVID-19 Trial

May 6 2021, 7:03 AM EDT

## Trevena Reports First Quarter 2021 Results

May 6 2021, 7:00 AM EDT

## Stock Overview

Symbol	TRVN
Exchange	Nasdaq
Market Cap	247.03m
Last Price	\$1.51
52-Week Range	\$1.00 - \$3.68

05/12/2021 04:00 PM EDT

## Investor Relations

LifeSci Advisors, LLC  
Dan Ferry  
Managing Director  
T: 617-430-7576  
[daniel@lifesciadvisors.com](mailto:daniel@lifesciadvisors.com)

## Management Team

### Carrie L. Bourdow

President and Chief Executive Officer

### Scott Applebaum

Chief Legal and Compliance Officer, SVP of Regulatory Affairs and Corporate Secretary

### Mark A. Demitrack, MD

Senior Vice President, Chief Medical Officer

### Barry Shin

Senior Vice President, Chief Financial Officer

### Robert T. Yoder

Senior Vice President, Chief Commercial Officer

### Joel S. Solomon, Esq.

Vice President, Legal & Compliance

### Linda Wase, MD

Vice President, Medical Affairs

### Michael S. Kramer

Vice President, Scientific Operations & Alliance Management

### Katrine Sutton

Vice President, Finance Planning & Analysis

### Michael J. Fossler, Pharm. D., Ph. D., F.C.P.

Vice President, Clinical Development and Quantitative Sciences

### Angela Bagley

Vice President, CMC and Supply Chain Operations

### Todd L. Wandstrat, BS Pharm, RPh, PharmD

Vice President, Health Economics and Medical Sciences

---

## Trevena, Inc.

955 Chesterbrook Blvd  
Suite 110  
Chesterbrook, PA 19087

---

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.

